OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

2 events
Oct 2020

Bronchitol®: FDA approved

as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use Bronchitol only for adults who have passed the Bronchitol Tolerance Test.

FDAcompleted
Feb 2013

Ravicti: FDA approved

Use as a nitrogen-binding agent for chronic management of adult and pediatric patients > or =2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Ravicti

Horizon Therapeutics USA, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk.
Search all trials →
Search clinical trials for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk

Recent News & Research

No recent news articles indexed yet for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk.
Search PubMed for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk

Browse all OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk news →

Specialist Network

No specialists currently listed for OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk.

View all OBSOLETE: Poliomyelitis in patients with immunodeficiencies deemed at risk specialists →

Quick Actions